aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA cash
Cash and short-term investments held at the end of each period.
aTYR PHARMA's cash was $57.42M at Jun 30, 2026. For fiscal 2025 it was $78.69M, up 9.1% from the year before. Over ten years it grew -1.9% a year on average. The highest annual figure on record is $107.91M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.69M | +9.1% |
| FY2024 | Dec 31, 2024 | $72.13M | -26.5% |
| FY2023 | Dec 31, 2023 | $98.17M | +48.4% |
| FY2022 | Dec 31, 2022 | $66.15M | -38.7% |
| FY2021 | Dec 31, 2021 | $107.91M | +240.5% |
| FY2020 | Dec 31, 2020 | $31.69M | +1.7% |
| FY2019 | Dec 31, 2019 | $31.14M | -37.1% |
| FY2018 | Dec 31, 2018 | $49.55M | -41.8% |
| FY2017 | Dec 31, 2017 | $85.12M | +18.0% |
| FY2016 | Dec 31, 2016 | $72.15M | -24.5% |
| FY2015 | Dec 31, 2015 | $95.54M | +502.6% |
| FY2014 | Dec 31, 2014 | $15.85M | -56.5% |
| FY2013 | Dec 31, 2013 | $36.46M | +892.0% |
| FY2012 | Dec 31, 2012 | $3.68M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $57.42M | -28.5% |
| Q1 FY2026 | Mar 31, 2026 | $66.51M | -12.9% |
| Q4 FY2025 | Dec 31, 2025 | $78.69M | +9.1% |
| Q3 FY2025 | Sep 30, 2025 | $85.15M | +29.0% |
| Q2 FY2025 | Jun 30, 2025 | $80.35M | +2.4% |
| Q1 FY2025 | Mar 31, 2025 | $76.35M | -9.6% |
| Q4 FY2024 | Dec 31, 2024 | $72.13M | -26.5% |
| Q3 FY2024 | Sep 30, 2024 | $65.99M | -35.4% |
| Q2 FY2024 | Jun 30, 2024 | $78.48M | -27.7% |
| Q1 FY2024 | Mar 31, 2024 | $84.50M | -26.1% |
| Q4 FY2023 | Dec 31, 2023 | $98.17M | +48.4% |
| Q3 FY2023 | Sep 30, 2023 | $102.13M | +32.0% |
| Q2 FY2023 | Jun 30, 2023 | $108.58M | +22.6% |
| Q1 FY2023 | Mar 31, 2023 | $114.39M | +15.9% |
| Q4 FY2022 | Dec 31, 2022 | $66.15M | -38.7% |
| Q3 FY2022 | Sep 30, 2022 | $77.37M | -33.5% |
| Q2 FY2022 | Jun 30, 2022 | $88.55M | +101.0% |
| Q1 FY2022 | Mar 31, 2022 | $98.67M | +94.8% |
| Q4 FY2021 | Dec 31, 2021 | $107.91M | +240.5% |
| Q3 FY2021 | Sep 30, 2021 | $116.35M | +221.9% |
| Q2 FY2021 | Jun 30, 2021 | $44.06M | +6.3% |
| Q1 FY2021 | Mar 31, 2021 | $50.64M | +1.6% |
| Q4 FY2020 | Dec 31, 2020 | $31.69M | +1.7% |
| Q3 FY2020 | Sep 30, 2020 | $36.15M | -5.0% |
| Q2 FY2020 | Jun 30, 2020 | $41.43M | -2.3% |
| Q1 FY2020 | Mar 31, 2020 | $49.83M | +15.8% |
| Q4 FY2019 | Dec 31, 2019 | $31.14M | -37.1% |
| Q3 FY2019 | Sep 30, 2019 | $38.06M | -32.0% |
| Q2 FY2019 | Jun 30, 2019 | $42.40M | -34.1% |
| Q1 FY2019 | Mar 31, 2019 | $43.02M | -41.9% |
| Q4 FY2018 | Dec 31, 2018 | $49.55M | -41.8% |
| Q3 FY2018 | Sep 30, 2018 | $55.96M | -38.1% |
| Q2 FY2018 | Jun 30, 2018 | $64.33M | +12.4% |
| Q1 FY2018 | Mar 31, 2018 | $74.10M | +19.6% |
| Q4 FY2017 | Dec 31, 2017 | $85.12M | +18.0% |
| Q3 FY2017 | Sep 30, 2017 | $90.38M | +28.1% |
| Q2 FY2017 | Jun 30, 2017 | $57.22M | – |
| Q1 FY2017 | Mar 31, 2017 | $61.93M | – |
| Q4 FY2016 | Dec 31, 2016 | $72.15M | – |
| Q3 FY2016 | Sep 30, 2016 | $70.53M | – |
See a number that looks wrong?